SCHEMBL16616376

SCHEMBL16616376

COc1ccc(Nc2ncccc2/C=C/C(=O)c2ccc(OC)c([N+](=O)[O-])c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
PAX8 Q06710 1/20 0.51
ALDH1A1 P00352 9/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
NPSR1 Q6W5P4 4/20 0.49
MAPK1 P28482 3/20 0.49
HTT P42858 2/20 0.49
LMNA P02545 4/20 0.49
POLB P06746 2/20 0.46
ATM Q13315 1/20 0.46
MAOB P27338 1/20 0.46
GAA P10253 2/20 0.46
KDM4E B2RXH2 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
DPP4 P27487 1/20 0.46
PREP P48147 1/20 0.46
DPP9 Q86TI2 1/20 0.46
NPC1 O15118 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16616377 1.00 MAPT (0.51) MAPTSMN1; SMN2PAX8ALDH1A1MEN1
SCHEMBL16616827 0.93 MAPT (0.49) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL16616830 0.93 MAPT (0.49) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL16625587 0.93 ALDH1A1 (0.49) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL16616474 0.93 KMT2A (0.55) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL16616476 0.93 KMT2A (0.55) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL16616250 0.92 MAPT (0.50) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL16616394 0.92 LMNA (0.48) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL16616395 0.92 LMNA (0.48) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL16616247 0.92 MAPT (0.50) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof HCCS, WEE2, WEE1 MAPT 2681/4885SMN1; SMN2 4456/4885PAX8 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.